Abbisko Therapeutics' Lavengratinib Gets EMA Orphan Designation for Achondroplasia

• Abbisko Cayman's subsidiary Abbisko Therapeutics received EMA orphan designation for lavengratinib (ABSK061) to treat achondroplasia on October 21, 2026.
• The drug previously received FDA orphan drug and rare pediatric disease designations; its investigational new drug application has cleared FDA review.
• Lavengratinib is undergoing a Phase II trial in children ages 3-12 with achondroplasia.
• Preliminary trial data showed positive growth signals, with favorable overall safety and tolerability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261021-12377748), on October 21, 2026, and is solely responsible for the information contained therein.